|
This publication is made possible by an educational grant from Amgen
Inc.
|
Volume 51, Number
4
Drug-Induced
Rheumatic Syndromes
Raymond
Yung, MD
Department of Internal Medicine
University of Michigan
Ann Arbor, MI
Bruce
Richardson, MD, PhD
Department of Internal Medicine
Ann Arbor Veterans Affairs Medical Center
Ann Arbor, MI
References
1.
Hoffman BJ. Sensitivity of sulfadiazine resembling acute disseminated
lupus erythematosus. Arch Dermatol Syph 1945;51:190-2.
2.
Yung RL, Richardson BC. Drug-induced
lupus. Rheum Dis Clin North Am
1994; 20:61-86.
3.
3. Zarrabi MH, Zucker S, Miller F, et al. Immunologic and coagulation
disorders in chlorpromazine-trested patients. Ann Intern Med 1979;91:194-9.
4.
4. Canoso RT, de Oliviera RM. Chlorpromazine-induced anticardiolipin
antibodies and lupus anticoagulant: ansebce of thrombosis. Am J Hematol
1988;27:272-5.
5.
5. Schlienger RG, Bircher AJ, Meier CR. Minocycline-induced lupus. A
systemic review. Dermatol 2000;200:223-31.
6.
6. Elkayam O, Yaron M, Caspi D. Minocycline-induced autoimmune syndromes: an
overview. Semin Arthritis Rheum 1999;28:392-7
7.
7. Ioannou Y, Isenberg DA. Review: Current evidence for the induction of
autoimmune rheumatic manifestations by cytokine therapy. Arthritis Rheum 2000,
43:1431-41.
8.
8. Ronnblom LE, Alm GV, Oberg KE. Possible induction of systemic lupus
eryhtematosus by interferon-alpha treatment in a patient with a malignant
carcinoid tumour. J Intern Med 1990;227:207-10.
9.
9. Okanoue T, Sakamoto S, Itoh Y, Minami M, Yasui K, Sakamoto M et al: Side
effects of high-dose interferon therapy for chronic hepatitis C. J Hepatol
1996;25:283-91.
10. 10.
Ronnblom LE, Alm GV, Oberg KE. Autoimmunity after alpha-interferon
therapy for malignant carcinoid tunors. Ann Intern Med 1991;115:178-83.
11.
11. 11. Charles PJ, Smeenk RJT, De Jong J, Feldmann M, Maini RN. Assessment of
antibodies to double-stranded DNA induced in rheumatoid arthritis patients
following treatment with infliximab, a monoclonal antibody to tumor necrosis
factor a. Arthritis Rheum 2000;43:2383-90.
12.
12. Calabrese LH, Duna GF. Drug-induced vasculitis. Curr Opin Rheumatol.
1996;8:34-40.
13. 13.
Choi HK, Slot MC, Pan G, Weissbach CA, Niles JL, Merkel PA. Evaluation of
antineutrophil cytoplasmic antibody seroconversion induced by minocycline,
sulfasalazine, or penicillamine. Arthritis Rheum 2000;43:2488-92.
14.
14. Jain KK. Cutaneous vasculitis associated with granulocyte
colony-stimulating factor. J Am Acad Dermatol. 1994;31:213-5.
15.
15. Brown MA, Bertouch JV. Rheumatic complications of influenza vaccination.
Aust N Z J Med. 1994;24:572-3.
16. 16.
Zaas A, Scheel P, Venbrux A, Hellmann DB. Large artery vasculitis
following recombinant hepatitis B vaccination: 2 cases. J Rheumatol
2001;28:1116-20.
17.
17. Courtney PA, Patterson RN, Lee RJ. Henoch-Schonlein purpura following
meningitis C vaccination. Rheumatology 2001;40:345-6.
1 . 18. Jamaleddine G, Diab K, Tabbarah Z, Tawil A, Arayssi T. Leukotriene
antagonists and the Churg-Strauss Syndrome. Semin Arthritis Rheum
2002;31:218-27.
19.
19. Masi A, Hamilos DL. Leukotriene antagonists: bystanders or causes of
Churg-Strauss Syndrome. Semin Arthritis Rheum 2002;31:211-7.
20.
20. Galaria NA, Werth VP, Schumacher HR. Leukocytoclastic vasculitis due to
etanercept. J Rheumatol 2000;27(8):2041-4.
1. 21.
Cunnane G, Warnock M, Rehman Q, Fye K, Gaikh San DI. Accelerated
nodulosis and vasculitis following etanercept therapy for rheumatoid arthritis.
Arthritis Rheum 2001;44(3):S373.
22.
22. Stone JH, Uhlfelder ML, Hellmann DB, Crook S, Bedocs NM, Hoffman GS.
Etanercept combined with conventional treatment in Wegener's granulomatosis: a
six-month open-label trial to evaluate safety. Arthritis Rheum
2001;44(5):1149-54.
23.
23. Miller FW, Hess EV, Clauw DJ, Hertzman PA,
et al. Approaches for identifying and defining environmentally associated
rheumatic disorders. Arthritis Rheum 2000;43:243-9.
| 
